FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease

SRP-9001, an experimental gene therapy that aims to slow or stop the progression of Duchenne muscular dystrophy, is being considered for accelerated approval by the FDA.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news